老年2型糖尿病血糖控制、磺脲类与胰岛素治疗与严重低血糖及死亡风险
基于英国CPRD数据库2000–2017年≥70岁2型糖尿病患者的观察性研究,比较连续三次HbA1c<7%且使用胰岛素和/或磺脲类者(暴露组)与未暴露者。暴露组严重低血糖住院风险显著升高(调整HR 2.52,95%CI 2.23–2.84),心血管与非心血管死亡风险无明确增加。磺脲类和胰岛素使用比血糖水平更能预测严重低血糖和死亡。
要点
- 老年2型糖尿病低HbA1c且用磺脲类/胰岛素者严重低血糖住院风险增约2.5倍
- 该人群心血管与非心血管死亡风险未见明确增加
- 磺脲类和胰岛素使用比血糖水平更能预测严重低血糖和死亡
核心结论
- 老年2型糖尿病低HbA1c并使用磺脲类或胰岛素者严重低血糖住院风险显著升高,但死亡风险无明确增加证据。
研究设计与样本
- 观察性研究,纳入英国CPRD基层数据库2000–2017年≥70岁2型糖尿病患者,暴露组为连续三次HbA1c<7%(53 mmol/mol)且此前60天内使用胰岛素和/或磺脲类者,与未暴露者匹配比较。
- 共纳入22,857名受试者,暴露组6,288人(27.5%),其中5,659人(90.0%)使用磺脲类。
主要发现
- 随访期间发生10,878例死亡(47.6%)和1,392例严重低血糖事件(6.1%)。
- 暴露组 vs 未暴露组严重低血糖调整HR 2.52(95%CI 2.23–2.84),心血管死亡调整HR 0.98(0.91–1.06),非心血管死亡调整HR 1.05(0.99–1.11)。
- 70、75、80、85岁者10年严重低血糖风险分别比未暴露者高7.7%、8.1%、8.6%、8.4%;非心血管死亡风险差异从70岁1.2%(95%CI -0.1–2.5)到85岁1.6%(-0.2–3.4)。
- 磺脲类和胰岛素使用比血糖水平更是严重低血糖和死亡的预测因素。
临床怎么用
- 老年2型糖尿病患者使用磺脲类或胰岛素时,应警惕严重低血糖风险,尤其HbA1c偏低者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the relative and absolute risk of severe hypoglycemia and mortality associated with glucose control, sulfonylureas, and insulin treatment in elderly people with type 2 diabetes. RESEARCH DESIGN AND METHODS: We identified elderly subjects (≥70 years old) with type 2 diabetes between 2000 and 2017 in the U.K. Clinical Practice Research Datalink primary care database with linkage to hospitalization and death data. Subjects with three consecutive HbA1c values <7% (53 mmol/mol) while on insulin and/or sulfonylureas within 60 days prior to the third HbA1c value (exposed) were matched with subjects not exposed. Hazard ratios (HRs) and absolute risks were estimated for hospitalizations for severe hypoglycemia and cardiovascular and noncardiovascular-related mortality. RESULTS: Among 22,857 included subjects (6,288 [27.5%] exposed, of whom 5,659 [90.0%] were on a sulfonylurea), 10,878 (47.6%) deaths and 1,392 (6.1%) severe hypoglycemic episodes occurred during the follow-up. In comparison with nonexposed subjects, the adjusted HR in exposed subjects was 2.52 (95% CI 2.23, 2.84) for severe hypoglycemia, 0.98 (0.91, 1.06) for cardiovascular mortality, and 1.05 (0.99, 1.11) for noncardiovascular mortality. In a 70-, 75-, 80-, and 85-year-old subject, the 10-year risk of severe hypoglycemia was 7.7%, 8.1%, 8.6%, and 8.4% higher than in nonexposed subjects, while differences for noncardiovascular mortality ranged from 1.2% (95% CI -0.1, 2.5) in a 70-year-old to 1.6% (-0.2, 3.4) in an 85-year-old subject. Sulfonylurea and insulin use were more relevant predictors of severe hypoglycemia and death than were glucose levels. CONCLUSIONS: Elderly subjects with type 2 diabetes and low HbA1c on sulfonylurea or insulin treatment experienced a substantially higher risk of hospitalization for severe hypoglycemia but had no clear evidence of increased risks of mortality.
引用
- Ling S, Zaccardi F, Lawson C, et al. Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study. Diabetes Care. 2021. PMID: 33541857. doi:10.2337/dc20-0876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。